)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Climb Bio
Climb Bio (CLYM) investor relations material
Climb Bio Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary9 Mar, 2026
Strategic overview and pipeline focus
Emphasis on execution in 2025, with foundational work enabling a rich data year in 2026 across both lead programs.
Focus on B-cell mediated diseases using monoclonal antibodies, with budoprutug (CD19 mAb) as the lead asset and a newly in-licensed APRIL-only antibody (CLYM116).
Differentiation from competitors by targeting broader B-cell populations and developing subcutaneous formulations for improved patient access.
Initial indications target areas with high unmet need and limited competition, such as PMN, ITP, SLE, and IgAN.
Synergies between programs in infrastructure and expertise, especially in renal and autoimmune indications.
Clinical development and upcoming data readouts
Subcutaneous healthy volunteer data for budoprutug expected in the first half of 2026, aiming to demonstrate comparable B-cell depletion to IV dosing.
Initial data from ITP, SLE, and PMN studies anticipated in the second half of 2026, focusing on early biomarkers, safety, and efficacy signals.
PMN study targets moderate to severe patients, with early biomarker and proteinuria data expected, but not full 1-year endpoints.
ITP study includes three dose cohorts (six patients each), focusing on treatment-refractory, third-line patients and platelet response as the primary endpoint.
SLE study designed for translational biomarker assessment rather than clinical endpoints, exploring potential for durable remission or chronic therapy.
Competitive landscape and product differentiation
CD19 targeting offers broader B-cell depletion than CD20, with clinical evidence supporting efficacy in diseases where CD20 therapies have failed.
Subcutaneous formulation of budoprutug may unlock new indications and improve patient convenience.
CLYM116 (APRIL-only antibody) features a sweeper mechanism, half-life extension, and potentially lower immunogenicity compared to competitors.
Head-to-head non-human primate data showed superior half-life and IgA suppression versus sibeprenlimab.
Market for IgAN expected to evolve rapidly, with APRIL-only therapies potentially preferred due to safety and efficacy profile.
Budo's 'white space' indication strategy
CLYM116's target IgAN patient profile
How will Climb fund pivotal trials for Budo/CLYM116?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Climb Bio earnings date
Q1 202613 May, 2026
Climb Bio
Next Climb Bio earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Eliem Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuronal excitability disorders, which are associated with conditions like chronic pain, epilepsy, depression, and anxiety. The company’s approach involves advancing clinical-stage compounds that target neurological diseases, aiming to address significant unmet medical needs. Eliem Therapeutics is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage